Skip to content

Dr. Gearóid Tuohy

Novartis AG (NYSE: NVS; SIX: NOVN) attains ex-US rights to develop and commercialize new gene therapy treatment for Leber’s congenital amaurosis (LCA).

Spark Therapeutics Inc. (NASDAQ:ONCE) have announced that the company has entered into a licensing and supply agreement for investigational voretigene neparvovec, branded in the US… Read More »Novartis AG (NYSE: NVS; SIX: NOVN) attains ex-US rights to develop and commercialize new gene therapy treatment for Leber’s congenital amaurosis (LCA).

12 year clinical study of retinal vein occlusion (RVO) in patients with end stage renal disease shows increased risk compared to control population.

A South Korean retrospective longitudinal clinical study of retinal vein occlusion (RVO) in patients with end stage renal disease (ESRD) has shown that a significant… Read More »12 year clinical study of retinal vein occlusion (RVO) in patients with end stage renal disease shows increased risk compared to control population.

Stem cell researchers characterize RPE maturation processes required in order to maximise potential of transplanted cells.

Collaborative research, led by investigators at the Institute of Molecular Physiology, Johannes-Gutenberg University, Mainz, Germany, and the US National Eye Institute, NIH, Bethesda, Maryland, have… Read More »Stem cell researchers characterize RPE maturation processes required in order to maximise potential of transplanted cells.

Review of price tag for Spark Therapeutics’ gene therapy treatment (Luxturna, $850,000 per patient) suggests a discount of up to 90% in certain cases.

In a report published by the US Institute for Clinical and Economic Review (ICER), healthcare experts stated that the recently approved gene therapy for Leber’s… Read More »Review of price tag for Spark Therapeutics’ gene therapy treatment (Luxturna, $850,000 per patient) suggests a discount of up to 90% in certain cases.

Biomarkers of metabolism, easily detectable with SD-OCT, indicate association with successful treatment of DME with DEX implant.

Collaborative clinical research by clinicians based in Tel Aviv University, Israel, University of Buenos Aires, Argentina, the University of Leipzig, Germany and the University of… Read More »Biomarkers of metabolism, easily detectable with SD-OCT, indicate association with successful treatment of DME with DEX implant.